Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul

INTEGRA LIFESCIENCES HOLDINGS CORP

Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
Mojdeh Poul departed as President and CEO and from the Board effective April 30, 2026; she receives $566,526 lump sum.
Essig receives $1,075,000 base salary, 125% target bonus, and initial equity awards totaling $8 million in RSUs and options.
Michael McBreen appointed Chief Commercial Officer with base salary $660,000 and $1,000,000 one-time equity award.
Essig previously served as Integra's CEO from 1997 to 2012 and as Executive Chairman from February 2024 to June 2025.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stuart M. Essig

President and Chief Executive Officer

IART · INTEGRA LIFESCIENCES HOLDINGS CORP

Effective: 2026-05-01
Successor: Stuart M. Essig
Filed: May 5, 2026, 7:59 PM ET

On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").

Departed

Mojdeh Poul

Director

IART · INTEGRA LIFESCIENCES HOLDINGS CORP

Effective: 2026-04-30
Successor: Stuart M. Essig
Filed: May 5, 2026, 7:59 PM ET

Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").

Departed

Mojdeh Poul

President and Chief Executive Officer

IART · INTEGRA LIFESCIENCES HOLDINGS CORP

Effective: 2026-04-30
Successor: Stuart M. Essig
Filed: May 5, 2026, 7:59 PM ET

Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stuart M. Essig was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mojdeh Poul departed as Director at INTEGRA LIFESCIENCES HOLDINGS CORP.

Action: departed
Role: Director

Exact text from the filing

Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mojdeh Poul departed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

Action: departed
Role: President and Chief Executive Officer

Exact text from the filing

Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").

View on SEC.gov

INTEGRA LIFESCIENCES HOLDINGS CORP filing history →

Source: SEC EDGAR

accession 0000917520-26-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.